Mirion Technologies, Inc. (MIR) Stock Price & Analysis
Mirion Technologies, Inc. (MIR) fell 1.51% to USD 17 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
MIR last closed at USD 17.26; the session ranged USD 16.44–17.61 on volume of 1,689,634 shares. Market capitalization is $4.16B, with a 52-week range of USD 16.43–30.28 (NYQ). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 17 |
|---|---|
| Change | ▼ 1.51% (down) |
| Previous Close | USD 17.26 |
| Open | USD 17.39 |
| Day Range | USD 16.44 – 17.61 |
| 52-Week Range | USD 16.43 – 30.28 |
| Volume | 1,689,634 shares |
| Market Cap | $4.16B |
| Exchange | NYQ |
Technical Analysis (MIR)
Nexqual's technical model rates MIR "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.96 (neutral) |
| vs SMA50 | Below (USD 18.77) |
| MACD | -0.46 (negative) |
Analyst Ratings (MIR)
Wall Street analysts rate MIR "None" based on 10 analysts, with a mean price target of USD 27.9 (range USD 26–29), per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 27.9 |
| High Target | USD 29 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (MIR)
| Next Earnings Date | 2026-07-28 |
|---|---|
| EPS Estimate | USD 0.1 |
| Revenue Estimate | $269.90M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.1 vs est 0.09 ▲ beat |
| 2025-12-31 | USD 0.15 vs est 0.17 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.1 ▲ beat |
| 2025-06-30 | USD 0.11 vs est 0.1 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (MIR)
| Total Revenue | $981.00M |
|---|---|
| Revenue Growth (YoY) | +27.50% |
| Gross Margin | +47.09% |
| Operating Margin | +1.44% |
| Profit Margin | +2.56% |
| ROE | +1.51% |
| Debt / Equity | 65.34 |
| Current Ratio | 3.19 |
| Total Cash | $404.90M |
| Total Debt | $1.23B |
| Free Cash Flow | $68.01M |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (MIR)
Nexqual rates Mirion Technologies, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 47%, operating 1% |
| Balance Sheet | Strong — $405M cash vs $1.23B debt |
| Cash Flow | Solid — FCF $68M, 7% margin |
| Efficiency | Weak — ROE 2%, ROA 1.3% |
Ownership (MIR)
| Insider Ownership | +3.39% |
|---|---|
| Institutional Ownership | +110.39% |
| Shares Outstanding | 244.66M |
| Float | 225.35M |
| Short % of Float | +17.75% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (MIR)
Mirion Technologies, Inc. is led by Thomas D. Logan (age 64), Founder, Medical Group President, CEO & Chairman, per Nexqual as of June 9, 2026 at 23:51 UTC.
| Founder, Medical Group President, CEO & Chairman | Thomas D. Logan (age 64) |
|---|---|
| CFO & Medical Group President | Brian Schopfer (age 40) |
| Group President of Nuclear & Safety Technologies | Loic Eloy (age 48) |
| Chief Technology Officer | James Francis Charles Cocks |
| Vice President of Investor Relations | Eric Linn |
Major Backers & Investors (MIR)
Notable institutional backers of Mirion Technologies, Inc. include T. Rowe Price, Cooperman, Leon G., Goldman Sachs, according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 8.87% |
| Cooperman, Leon G. | 3.43% |
| Goldman Sachs | 3% |
| FMR, LLC | 2.68% |
| Millennium Management | 2.09% |
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 1.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 23.86% |
| Vanguard Group | 21.41% |
| State Street | 3.85% |
| Geode Capital | 2.43% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
From Mirion Technologies, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We differentiate our products and technologies primarily through our proprietary know-how, technology or data that are not covered by patents or patent applications, including technical processes, equipment designs, testing and other procedures.
- Our track record enables us to gain market share across our product and service offerings.
- Intellectual Property The success of our business depends, in part, on our ability to maintain and protect our proprietary technologies, information, processes and know-how.
- Due to the long useful life of certain aspects of our technology, we believe that the patent registration process, which requires public disclosure of patented claims and inventions, could harm our competitive position.
Partnerships
- Where appropriate, we require third parties with whom we deal to enter into agreements with us that address issues of confidentiality and intellectual property.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | USD 17.92 | ▲ 5.16% |
| EP | Empire Petroleum Corporation | USD 2.85 | ▲ 5.56% |
| AES | The AES Corporation | USD 14.66 | ▼ 0.07% |
| CMS | CMS Energy Corporation | USD 72.63 | ▲ 0.82% |
| NRG | NRG Energy, Inc. | USD 129.96 | ▲ 0.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.